| Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system MS Aymerich, E Aso, MA Abellanas, RM Tolon, JA Ramos, I Ferrer, ... Biochemical pharmacology 157, 67-84, 2018 | 116 | 2018 |
| Gut microbial dysbiosis after traumatic brain injury modulates the immune response and impairs neurogenesis M Celorrio, MA Abellanas, J Rhodes, V Goodwin, J Moritz, S Vadivelu, ... Acta neuropathologica communications 9, 1-22, 2021 | 84 | 2021 |
| Midbrain microglia mediate a specific immunosuppressive response under inflammatory conditions MA Abellanas, M Zamarbide, L Basurco, E Luquin, M Garcia-Granero, ... Journal of neuroinflammation 16, 1-15, 2019 | 54 | 2019 |
| Dopamine Receptor D3 Expression Is Altered in CD4+ T-Cells From Parkinson's Disease Patients and Its Pharmacologic Inhibition Attenuates the Motor … D Elgueta, F Contreras, C Prado, A Montoya, V Ugalde, O Chovar, ... Frontiers in immunology 10, 981, 2019 | 51 | 2019 |
| Microglia and astrocyte activation is region‐dependent in the α‐synuclein mouse model of Parkinson's disease L Basurco, MA Abellanas, L Ayerra, E Conde, R Vinueza‐Gavilanes, ... Glia 71 (3), 571-587, 2023 | 42 | 2023 |
| The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced … E Rojo-Bustamante, MA Abellanas, P Clavero, ML Thiolat, Q Li, ... Neurobiology of Disease 118, 64-75, 2018 | 30 | 2018 |
| Expression of endothelial NOX5 alters the integrity of the blood-brain barrier and causes loss of memory in aging mice A Cortés, M Solas, Á Pejenaute, MA Abellanas, M Garcia-Lacarte, ... Antioxidants 10 (8), 1311, 2021 | 20 | 2021 |
| The brain-immune ecosystem: Implications for immunotherapy in defeating neurodegenerative diseases M Schwartz, MA Abellanas, A Tsitsou-Kampeli, S Suzzi Neuron 110 (21), 3421-3424, 2022 | 16 | 2022 |
| CB2 receptors and Neuron–Glia interactions modulate neurotoxicity generated by MAGL inhibition E Rojo-Bustamante, I Íñigo-Marco, MA Abellanas, R Vinueza-Gavilanes, ... Biomolecules 10 (8), 1198, 2020 | 12 | 2020 |
| Cannabinoid receptor type 2 as a therapeutic target for Parkinson's disease MA Abellanas, MS Aymerich Diagnosis and management in Parkinson's disease, 557-573, 2020 | 5 | 2020 |
| Nigrostriatal degeneration determines dynamics of glial inflammatory and phagocytic activity L Ayerra, MA Abellanas, L Basurco, I Tamayo, E Conde, A Tavira, A Trigo, ... Journal of Neuroinflammation 21 (1), 92, 2024 | 2 | 2024 |
| Chronological versus immunological aging: Immune rejuvenation to arrest cognitive decline L Basurco, MA Abellanas, M Purnapatre, P Antonello, M Schwartz Neuron 113 (1), 140-153, 2025 | | 2025 |
| Monocyte-derived macrophages act as reinforcements when microglia fall short in Alzheimer’s disease MA Abellanas, M Purnapatre, C Burgaletto, M Schwartz Nature Neuroscience, 1-10, 2025 | | 2025 |
| Activation of central cannabinoid type 2 receptors, but not on peripheral immune cells, is required for endocannabinoid-mediated neuroprotection in Parkinson´ s disease L Ayerra, MA Abellanas, C Vidaurre, L Basurco, A Tavira, E Luquin, ... | | 2024 |
| Brain catecholaminergic neurons control monocytes deployment to sites of injury and their loss exacerbate cognitive deterioration in an animal model of Alzheimer’s Disease T Croese, MA Abellanas, JMP Ramos, M Arad, S Medina, G Castellani, ... Alzheimer's & Dementia 19, e080263, 2023 | | 2023 |
| CD4 T CELL MODULATION IS NEUROPROTECTIVE IN AN AAV9-MEDIATED A-SYNUCLEIN OVEREXPRESSION MOUSE MODEL OF PARKINSON´ S DISEASE A Tavira, L Basurco, MA Abellanas, L Ayerra, R Vinueza-Gavilanes, ... IBRO Neuroscience Reports 15, S291-S292, 2023 | | 2023 |
